Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Equities researchers at Jefferies Group raised their FY2017 EPS estimates for shares of Intellia Therapeutics in a research note issued to investors on Tuesday. Jefferies Group analyst M. Raycroft now forecasts that the company will earn ($1.74) per share for the year, up from their prior forecast of ($1.99). Jefferies Group currently has a “Buy” rating and a $42.00 price target on the stock. Jefferies Group also issued estimates for Intellia Therapeutics’ Q4 2017 earnings at ($0.49) EPS, FY2018 earnings at ($2.34) EPS, FY2019 earnings at ($2.78) EPS, FY2020 earnings at ($2.44) EPS and FY2021 earnings at ($2.31) EPS.

Other analysts have also recently issued reports about the stock. Zacks Investment Research raised shares of Intellia Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, October 4th. Cann restated a “hold” rating on shares of Intellia Therapeutics in a report on Tuesday, August 1st. Chardan Capital reiterated a “buy” rating and issued a $20.00 price objective (up previously from $19.00) on shares of Intellia Therapeutics in a report on Wednesday, August 2nd. Leerink Swann boosted their price objective on shares of Intellia Therapeutics from $29.00 to $37.00 and gave the stock an “outperform” rating in a report on Tuesday. They noted that the move was a valuation call. Finally, TheStreet upgraded shares of Intellia Therapeutics from a “d+” rating to a “c-” rating in a report on Thursday, July 6th. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $29.50.

WARNING: “Intellia Therapeutics, Inc. (NTLA) Expected to Post FY2017 Earnings of ($1.74) Per Share” was posted by American Banking News and is the property of of American Banking News. If you are reading this report on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/11/02/intellia-therapeutics-inc-ntla-expected-to-post-fy2017-earnings-of-1-74-per-share.html.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Tuesday, October 31st. The company reported ($0.44) EPS for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.06. Intellia Therapeutics had a negative return on equity of 27.19% and a negative net margin of 215.92%. The firm had revenue of $7.30 million for the quarter, compared to analysts’ expectations of $5.83 million. During the same period in the prior year, the firm posted ($0.22) earnings per share. The firm’s quarterly revenue was up 49.0% on a year-over-year basis.

Several large investors have recently made changes to their positions in NTLA. ARK Investment Management LLC grew its position in Intellia Therapeutics by 118.9% in the 2nd quarter. ARK Investment Management LLC now owns 174,810 shares of the company’s stock worth $2,797,000 after purchasing an additional 94,960 shares during the last quarter. Vanguard Group Inc. grew its position in Intellia Therapeutics by 10.2% in the 2nd quarter. Vanguard Group Inc. now owns 997,288 shares of the company’s stock worth $15,957,000 after purchasing an additional 92,580 shares during the last quarter. OxFORD Asset Management LLP bought a new position in Intellia Therapeutics in the 2nd quarter worth about $1,132,000. GSA Capital Partners LLP bought a new position in Intellia Therapeutics in the 2nd quarter worth about $907,000. Finally, State Street Corp grew its position in Intellia Therapeutics by 52.0% in the 2nd quarter. State Street Corp now owns 164,798 shares of the company’s stock worth $2,638,000 after purchasing an additional 56,363 shares during the last quarter. 47.77% of the stock is owned by institutional investors and hedge funds.

About Intellia Therapeutics

Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.

Earnings History and Estimates for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.